Vir to receive $90 million upfront in Gilead cancer treatment deal
Key Facts
Vir Biotechnology announced a collaboration and licensing agreement with Gilead Sciences on October 14, 2026, to develop treatments for solid tumors, with upfront consideration of $90 million. The company said in a statement accompanying its U.S. Securities and Exchange Commission filing that the funding combines a cash payment and an equity investment. The cash payment totals $65 million, while the equity investment is valued at $25 million. The companies signed the collaboration and licensing agreement on October 9, 2026, before announcing it and the stock purchase agreement. The collaboration aims to discover immunotherapies using dual-masked T-cell engager technology, in exchange for rights giving Gilead a role in their development and commercialization.
Under the investment agreement, Gilead agreed to buy 1,765,486 shares of Vir common stock, according to the U.S. company's filing. The agreement set the share issuance price at $14.16 per share, with completion subject to customary closing conditions. Vir said the investment carries a 30% premium, adding the stock purchase to the cash consideration as part of the collaboration's upfront funding. The equity agreement also includes restrictions on Gilead increasing its stake, voting and selling shares, subject to customary exceptions specified in the agreement. These restrictions expire a year after the expected closing of the investment, according to the terms in the regulatory filing.
Subsequent payments are tied to future milestones in the treatment programs and become payable only upon reaching the stages specified in the agreement. Vir could receive up to $45 million for near-term preclinical milestones, according to agreement details published by Investing.com. The terms also include potential additional payments of up to $1.74 billion across development, regulatory and commercial milestones. The bulk of the collaboration's financial consideration is therefore tied to the treatment candidates' progress through these milestones, through to commercialization. Vir cautioned in its filing on the agreement that early trial results "do not guarantee regulatory approval."
The collaboration covers the discovery and design of 3 new treatment candidates targeting selected antigens associated with solid tumors, according to Vir's filing on the agreement. Vir will handle discovery, design and optimization, the research work that precedes the programs' transition to subsequent development. Gilead will receive an exclusive license for development and commercialization and assume responsibility for subsequent development activities, manufacturing and commercialization, according to collaboration details published by Investing.com. In antibody discovery, Vir uses a platform drawing on both open-source and proprietary artificial intelligence tools. Vir says in its description of the discovery platform that these tools allow antibody properties to be optimized simultaneously during the design process.
Vir describes the masking technology used in the collaboration as designed to keep the drug inactive as it circulates through the body, aiming to reduce unwanted effects on healthy tissue. The drug is activated within the tumor environment by protease enzymes, according to the explanation of the platform on the company's website. The covering used in the technology also helps extend the drug's lifetime in the blood, giving it time to reach the tumor. Vir previously obtained an exclusive worldwide license to use the masking technology under an agreement with Sanofi, according to its annual report filed with the U.S. regulator. That license covers use of the technology in oncology and infectious diseases, with ophthalmology excluded from the rights granted.
The Gilead agreement follows an earlier collaboration Vir signed with Astellas to develop the treatment candidate VIR-5500 for prostate cancer, according to the companies' statement filed with the U.S. Securities and Exchange Commission. That collaboration provided for upfront consideration and near-term milestone payments totaling $335 million. Vir also announced that VIR-5500 had received Fast Track designation from the U.S. Food and Drug Administration. The designation covers treatment of metastatic castration-resistant prostate cancer in patients in later lines of therapy, according to the company's statement on the candidate. Vir expects to begin Phase 3 trials in 2027 under its existing program with Astellas.